Summer 2027

IT Intern

Summer 2027

Updated on 9/8/2026

Deadline 10/16/26
Medtronic

Medtronic

10,001+ employees

Medical device maker advancing therapies

Compensation Overview

$23.25 - $33.25/hr

No H1B Sponsorship

Minneapolis, MN, USA

Hybrid

Interns must reside in the U.S. for the internship and work on-site at least four days per week.

Bachelor's

Category
IT Operations
Required Skills
Power BI
Python
Data Visualization
SQL
Word/Pages/Docs
AWS
Data Analysis
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to Medtronic

See people who can refer or advise you

Requirements
  • Working toward a bachelor's degree in management information systems, computer information systems, business information systems, a related information systems major, or business analytics, with anticipated graduation in Winter 2027 or Spring 2028.
  • Ability to participate full time for 40 hours per week during the internship cohort from June 1 through August 14 for semester-system programs or June 15 through August 21 for quarter-system programs.
  • Currently authorized to work in the United States without current or future employment sponsorship.
  • For baccalaureate degrees earned outside the United States, possession of a degree satisfying 8 C.F.R. § 214.2(h)(4)(iii)(A).
Responsibilities
  • Develop digital healthcare and virtual reality platforms that enable collaboration among patients, doctors, and hospital networks.
  • Use human-centered design principles to improve system usability for employees and customers.
  • Leverage data analytics and statistical methods to develop business-centric insights supporting decision-making.
  • Identify and recommend ways to save money and time by streamlining business processes, applications, and systems.
  • Assess Global IT security and identify solutions to mitigate risk.
Desired Qualifications
  • A minimum cumulative GPA of 3.0 on a 4.0 scale.
  • Familiarity with Microsoft Office Suite, including Excel, PowerPoint, and Word, Power BI, Amazon Web Services, Structured Query Language, Python, or similar technologies.
  • Experience developing dashboards, reports, data visualizations, or data-driven insights.
  • Experience collaborating on team-based academic, research, internship, or organizational projects.
  • Relevant coursework, projects, research, certifications, or internship experience in information technology, computer science, data analytics, business analytics, engineering, or related fields.
  • Experience applying data analysis and technical skills to solve business or operational challenges.

Medtronic makes medical devices and therapies to treat chronic diseases, including implantables, sensors, and diabetes management tools. Its devices interact with the body to regulate or monitor functions, such as pacemakers delivering heart stimulation and neuromodulation devices sending electrical signals. The company differentiates itself through a long history of device development and a broad portfolio, expanded via acquisitions to access new technologies and markets. Its goal is to improve patient health outcomes by providing integrated medical technologies that help manage chronic conditions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Fridley, Minnesota

Founded

1949

Get referred to Medtronic

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • First-quarter fiscal 2027 organic revenue rose 13.7%; guidance increased to 7.75%.
  • Cornerstone Robotics partnership and $700 million investment widen Hugo distribution beyond America.
  • Pi-Cardia deal opens 2027 exclusive ShortCut distribution and optional acquisition for TAVR growth.

What critics are saying

  • FDA class I recall of DLP Left Heart Vent Catheters hit August 2026.
  • MiniMed still carries diabetes execution risk after April 2026 IPO and pending separation.
  • Hugo faces Intuitive Surgical and J&J; robotics economics remain unproven at scale.

What makes Medtronic unique

  • Medtronic spans cardiovascular, neuroscience, surgical, and diabetes platforms across 150 countries.
  • Hugo plus Sentire gives Medtronic a rare two-robot portfolio outside the United States.
  • Affera, Sphere-9, and ShortCut extend one salesforce across ablation, TAVR, and robotics.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Employee Assistance Program

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Today's Medical Developments
Sep 4th, 2026
Medtronic announces partnerships, investments with Cornerstone Robotics and Pi-Cardia.

Medtronic announces partnerships, investments with Cornerstone Robotics and Pi-Cardia. The medtech company will gain access to surgical robotics and structural heart technology through the agreements. Published September 04, 2026 Medtronic announced a strategic partnership with Cornerstone Robotics, an innovative surgical robotics company committed to advancing minimally invasive surgery and improving access to the latest surgical care worldwide. The approximately $700 million investment includes rights to distribute Cornerstone Robotics' Sentire surgical system in select markets outside the U.S. where the system is market approved. Medtronic will distribute Sentire alongside its Hugo robotic-assisted surgery (RAS) system. Together with Medtronic's connected surgical ecosystem, the two complementary platforms will expand access to robotic-assisted surgery and offer surgeons and health systems more choice and flexible solutions designed to meet their diverse needs and reach more patients globally. With global adoption of robotic-assisted surgery still in the single digits, the opportunity to expand access to advanced surgical care for patients, physicians, and health systems around the world is significant. Expanded choice and access are critical drivers of the future of robotic assisted surgery. Through this partnership, Medtronic and Cornerstone Robotics are building a multi-port portfolio anchored by the Hugo RAS system and expanded by Sentire, giving customers meaningful flexibility across clinical settings, procedural needs, and economic models. "Our strategy is focused on driving the next generation of minimally invasive surgery, one of our biggest growth opportunities," says Matt Anderson, senior vice president and president, Surgical, Medtronic. "Surgeons, health systems and markets have varying needs and preferences, which is why we are investing across robotic platforms, digital tools, and platform-enhancing technologies. With Sentire complementing the Hugo RAS system, Medtronic will be the only company offering this two-platform portfolio combined with our surgical ecosystem - giving customers more access, more choice, and flexible solutions that fit their clinical and operational needs." Building on Hugo's momentum. The partnership builds on the momentum of Medtronic's Hugo RAS system, which is now being used in more than 35 countries across six continents, including the United States, where it received FDA clearance within the last year. Procedure growth for the Hugo RAS system is currently more than 2x the growth rate of the robotic surgery market, and total procedures are expected to exceed 50,000 globally by the end of Medtronic's fiscal year. Medtronic will continue to innovate the capabilities of the Hugo RAS system, including ongoing software upgrades, real-time artificial intelligence across its digital ecosystem, integrated stapling, expanded instrumentation, and clinical indications. The modular, multi-quadrant platform is designed for a broad range of soft-tissue surgical procedures and combines wristed instruments, 3D visualization, and Touch Surgery ecosystem with dedicated support for robotics program optimization, service, and training. Expanding access through Sentire surgical system. The Sentire system's architecture and immersive console with dual-console capability offer a familiar configuration suited to varying surgeon preferences and clinical needs. Developed entirely in-house by Cornerstone Robotics, Sentire has completed multi-specialty clinical trials and received CE Mark in May 2026 for use in minimally invasive general, gynecologic, thoracic, and urologic surgical procedures in addition to its market approval in China and Singapore. "Since the founding of Cornerstone Robotics, we have been steadfast in our commitment to innovation, excellence, and clinical value," says Samuel Au, founder and CEO, Cornerstone Robotics. "We are confident physicians and patients alike will be the greatest beneficiaries of this partnership as we continue to expand access across this dynamic market." Medtronic continues to invest across its surgical ecosystem to expand access to robotic-assisted solutions for operating rooms around the world. This partnership is another step in strengthening that connected ecosystem and advancing the company's commitment to improving the lives of patients through minimally invasive surgery. Investment in Pi-Cardia. Medtronic also announced a strategic investment in Pi-Cardia Ltd., a pioneer in leaflet modification technologies for structural heart disease. With a focus on addressing the evolving needs of increasingly complex transcatheter aortic valve replacement (TAVR) patients and procedures, Medtronic secures an option for strengthening its structural heart portfolio through this strategic investment, supporting the next generation of innovation. Pi-Cardia's ShortCut device is the first FDA-cleared leaflet modification technology designed to enable valve-in-valve TAVR procedures in patients at risk of coronary obstruction. The device provides physicians with a safe, easy-to-learn, reproducible approach to leaflet modification that can help preserve coronary access and enable future transcatheter valve procedures. In FDA-reviewed clinical studies, ShortCut demonstrated successful leaflet splitting in all pivotal trial patients and a favorable safety profile. "As structural heart care evolves, we're investing in technologies that help physicians address today's challenges while preparing for tomorrow's opportunities," says Jorie Soskin, vice president and general manager of the Structural Heart business within Medtronic's Cardiovascular portfolio. "Our investment in Pi-Cardia reflects our commitment to building a portfolio of technologies that will shape the future of TAVR, particularly for patients with complex anatomy. We believe leaflet modification technologies like ShortCut have the potential to become an important component of structural heart care and the future of TAVR as transcatheter therapies continue to advance." Under the agreement, Medtronic will make strategic investments of up to $80 million into Pi-Cardia and is expected to become the exclusive global commercial distributor of the ShortCut device in 2027. Medtronic will leverage its worldwide Structural Heart organization to expand physician access across the United States, Europe, Japan, and other international markets. The agreement also includes an option for Medtronic to acquire Pi-Cardia upon achievement of predefined milestones for an estimated upfront acquisition price of up to $210 million, subject to customary adjustments, plus additional potential earn-out payments post-acquisition that could meaningfully increase the total consideration. The transactions are subject to regulatory approval and customary closing conditions. "Our mission has been to make leaflet modification a standard part of complex TAVR," says Erez Golan, chief executive officer of Pi-Cardia. "Medtronic is the right partner to help us achieve this vision given their global reach and commitment to bringing innovative tools to physicians and patients worldwide. We are confident this collaboration will accelerate adoption of ShortCut while continuing to advance the future of leaflet modification." The strategic investment secures an option for Medtronic to strengthen its structural heart portfolio by adding a first-of-its-kind technology that addresses a significant challenge in valve-in-valve TAVR while complementing the company's leadership in transcatheter valve therapies. It also reflects Medtronic's commitment to partnering and investing early in innovations that can improve patient outcomes, expand future treatment options, and support long-term growth. Pi-Cardia was founded by Erez Golan and Eyal Kolka, and is backed by experienced medtech investors including Sofinnova Partners, Sprig Equity, and Jacques Séguin, whose commitment has helped advance the company's vision of developing transformative leaflet modification technologies. Get curated news on YOUR industry. Enter your email to receive its newsletters.

Medtronic
Sep 2nd, 2026
Medtronic Announces Strategic Partnership with Cornerstone Robotics to Further Expand Global Access to Robotic-Assisted Surgery

Partnership expands Medtronic's robotic-assisted surgery portfolio to expand access globally and gives surgeons and health systems more choice and flexibility $700 million investment includes...

Yahoo Finance
Sep 1st, 2026
Medtronic raises revenue guidance to 7.5% after Q1 growth of 13.7%, invests $700M in Cornerstone robotics

Medtronic reported 13.7% organic revenue growth in Q1 2027, driven by strong performance across its Cardiac Rhythm Management, Cranial & Spinal Technologies, and Surgical divisions. Cardiac Ablation Solutions grew 88%, powered by Sphere-9 share gains and the Affera mapping platform, which reached $2 billion in trailing 12-month revenue. The company raised full-year organic revenue growth guidance to 7.25% to 7.75%. An extra selling week in Q1 contributed approximately $570 million to growth, a one-off benefit. Medtronic announced a $700 million strategic investment in Cornerstone's Sentire Surgical System for global robotics distribution. The company also invested in Pi-Cardia, the first FDA-cleared leaflet modification technology for transcatheter aortic valve replacement. The planned separation of its Diabetes business is expected to close before fiscal year-end, expanding operating margins by 100 basis points.

MarketScreener
Sep 1st, 2026
Medtronic lifts outlook, invests over $700 million in heart tech & Robotics - update.

Medtronic lifts outlook, invests over $700 million in heart tech & Robotics - update. Published on 09/01/2026 at 07:52 am EDT By Connor Hart Medtronic raised its outlook for the year after posting higher fiscal first-quarter profit and sales, driven by broad-based demand and contributions from newer growth platforms. The medical-device maker also announced two separate investments totaling about $780 million, one supporting a heart-technology company and the other a surgical-robotics company. Medtronic Chief Financial Officer Thierry Piéton said strong operating performance and disciplined financial management drove adjusted per-share earnings and revenue higher during the recent quarter, giving the company confidence to raise its outlook. Shares recently rose 6.5% to $96.50 in premarket trading. The company now expects full-year adjusted earnings of $5.94 to $6 a share, raising the low-end of guidance by 4 cents. Revenue is now projected to grow 7.25% to 7.75% on an organic basis, up from a prior forecast of 6.75% to 7.25%. The new outlook came as Medtronic reported net income of $1.47 billion, or $1.14 a share, up from $1.04 billion, or 81 cents a share, in last year's comparable quarter. Stripping out one-time items, earnings were $1.45 a share. Analysts polled by FactSet expected adjusted earnings of $1.39 a share. Net sales climbed 14% to $9.76 billion, topping Wall Street models for $9.55 billion. On an organic basis, sales also rose 14%. Cardiovascular sales jumped 20% to $3.93 billion, making the unit Medtronic's largest top-line contributor. Sales across the company's neuroscience arm rose 10% to $2.68 billion, while sales across its medical-surgical business gained 10% to $2.28 billion. Separately, Medtronic on Tuesday said it will invest roughly $700 million in Cornerstone Robotics in exchange for the right to distribute its Sentire surgery system in select international markets. Along with Medtronic's own Hugo robotic-assisted surgery system, the two platforms will expand access, offering surgeons and health systems more choice and flexible solutions, the company said. Medtronic also agreed to invest up to $80 million in Pi-Cardia, whose ShortCut device is the first FDA-cleared leaflet modification technology designed to enable valve-in-valve, transcatheter aortic valve replacement procedures in patients at risk of coronary obstruction The agreement also includes an option for Medtronic to acquire Pi-Cardia upon achievement of predefined milestones for an estimated upfront acquisition price of up to $210 million, the companies said. Write to Connor Hart at [email protected] (END) Dow Jones Newswires 09-01-26 0752ET (C) Dow Jones - 2026

PR Newswire
Sep 1st, 2026
Medtronic announces strategic investment in Pi-Cardia to accelerate innovation for complex TAVR.

Medtronic announces strategic investment in Pi-Cardia to accelerate innovation for complex TAVR. Sep 01, 2026, 06:30 ET GALWAY, Ireland and REHOVOT, Israel, Sept. 1, 2026 /PRNewswire/ - Medtronic plc (NYSE: MDT), a global leader in healthcare technology, and Pi-Cardia Ltd., a pioneer in leaflet modification technologies for structural heart disease, today announced a strategic investment by Medtronic in Pi-Cardia Ltd. With a focus on addressing the evolving needs of increasingly complex transcatheter aortic valve replacement (TAVR) patients and procedures, Medtronic secures an option for strengthening its structural heart portfolio through this strategic investment, supporting the next generation of innovation. Pi-Cardia's ShortCut(TM) device is the first FDA-cleared leaflet modification technology designed to enable valve-in-valve TAVR procedures in patients at risk of coronary obstruction. The device provides physicians with a safe, easy-to-learn, reproducible approach to leaflet modification that can help preserve coronary access and enable future transcatheter valve procedures. In FDA-reviewed clinical studies, ShortCut(TM) demonstrated successful leaflet splitting in all pivotal trial patients and a favorable safety profile. "As structural heart care evolves, we're investing in technologies that help physicians address today's challenges while preparing for tomorrow's opportunities," said Jorie Soskin, vice president and general manager of the Structural Heart business within Medtronic's Cardiovascular portfolio. "Our investment in Pi-Cardia reflects our commitment to building a portfolio of technologies that will shape the future of TAVR, particularly for patients with complex anatomy. We believe leaflet modification technologies like ShortCut have the potential to become an important component of structural heart care and the future of TAVR as transcatheter therapies continue to advance." Under the agreement, Medtronic will make strategic investments of up to $80 million into Pi-Cardia and is expected to become the exclusive global commercial distributor of the ShortCut device in 2027. Medtronic will leverage its worldwide Structural Heart organization to expand physician access across the United States, Europe, Japan and other international markets. The agreement also includes an option for Medtronic to acquire Pi-Cardia upon achievement of predefined milestones for an estimated upfront acquisition price of up to $210 million, subject to customary adjustments, plus additional potential earn-out payments post-acquisition that could meaningfully increase the total consideration. The transactions are subject to regulatory approval and customary closing conditions. "Our mission has been to make leaflet modification a standard part of complex TAVR," said Erez Golan, Chief Executive Officer of Pi-Cardia. "Medtronic is the right partner to help us achieve this vision given their global reach and commitment to bringing innovative tools to physicians and patients worldwide. We are confident this collaboration will accelerate adoption of ShortCut while continuing to advance the future of leaflet modification." The strategic investment secures an option for Medtronic to strengthen its structural heart portfolio by adding a first-of-its-kind technology that addresses a significant challenge in valve-in-valve TAVR while complementing the company's leadership in transcatheter valve therapies. It also reflects Medtronic's commitment to partnering and investing early in innovations that can improve patient outcomes, expand future treatment options, and support long-term growth. Pi-Cardia was founded by Erez Golan and Eyal Kolka, and is backed by experienced medtech investors including Sofinnova Partners, Sprig Equity, and Jacques Séguin, whose commitment has helped advance the company's vision of developing transformative leaflet modification technologies. About Pi-Cardia Pi-Cardia Ltd. is a privately held medical device company dedicated to developing innovative structural heart technologies that address unmet clinical needs. Its proprietary leaflet modification platform is designed to improve procedural outcomes and expand treatment options for patients undergoing transcatheter valve interventions. About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission, to alleviate pain, restore health, and extend life, unites a global team of employees dedicated to transforming healthcare and improving lives around the world. Kimberly Powell Public Relations +1-202-498-2601 Ingrid Goldberg Investor Relations +1-763-505-2696 SOURCE Medtronic plc